Floatz logo

435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
Melanoma
Hassane M. Zarour, MDP2B (59)
Tuvonralimab
Melanoma
Hebei Medical University Fourth HospitalP4B (59)
Vibostolimab
Melanoma
Merck Sharp & Dohme LLCP3B (59)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Melanoma
Rapa Therapeutics LLCP2B (58)
Axitinib
Melanoma
Peking University Cancer Hospital & InstituteP2B (58)
Oncolytic Virus Rp1
Melanoma
Replimune, Inc.P3B (58)
Palbociclib
Melanoma
Peter MacCallum Cancer Centre, AustraliaP2B (58)
Recombinant Human Adenovirus Type 5
Melanoma
Fujian Cancer HospitalP2B (58)
Rituximab
Melanoma
Emory UniversityP2B (58)
Ruxotemitide
Melanoma
Oslo University HospitalP2B (58)
Tilsotolimod
Melanoma
A.J.M. van den EertweghP2B (58)
Tobemstomig
Melanoma
Hoffmann-La RocheP2B (58)
Adriamycin
Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2B (57)
lns8801
Melanoma
Linnaeus Therapeutics, Inc.P2/3B (57)
Pixatimod
Melanoma
Diwakar DavarP2B (57)
Scib1
Melanoma
Scancell LtdP2B (57)
Thymosin Alpha 1
Melanoma
Sun Yat-sen UniversityP2B (57)
Trastuzumab
Melanoma
Ascendis Pharma Oncology Division A/SP2B (57)
Atorvastatin
Melanoma
Erasmus Medical CenterP4B (56)
Bcd-217
Melanoma
BiocadP3B (56)
Darleukin
Melanoma
Philogen S.p.A.P3B (56)
Enzalutamide
Melanoma
MacroGenicsP2B (56)
Fianlimab
Melanoma
M.D. Anderson Cancer CenterP3B (56)
Imsamotide
Melanoma
IO BiotechP3B (56)
Intismeran Autogene
Melanoma
Merck Sharp & Dohme LLCP3B (56)
io102-io103
Melanoma
IO BiotechP3B (56)
Lifileucel
Melanoma
Iovance Biotherapeutics, Inc.P3B (56)
Lispro-Ph20 Component Rhuph20
Melanoma
Bristol-Myers SquibbP3B (56)
Metformin
Melanoma
Dan ZandbergP2B (56)
oh2
Melanoma
Binhui Biopharmaceutical Co., Ltd.P3B (56)
Pucotenlimab
Melanoma
Binhui Biopharmaceutical Co., Ltd.P2B (56)
Tislelizumab
Melanoma
HiFiBiO TherapeuticsP2B (56)
[203pb]vmt01
Melanoma
Perspective TherapeuticsP1/2CCC (55)
anv419
Melanoma
Vall d'Hebron Institute of OncologyP2CCC (55)
Capivasertib
Melanoma
M.D. Anderson Cancer CenterP2CCC (55)
Celecoxib
Melanoma
Roswell Park Cancer InstituteP2CCC (55)
gc101
Melanoma
Shanghai Juncell TherapeuticsP2CCC (55)
her2bbζ/cd19t+ t cells
Melanoma
M.D. Anderson Cancer CenterP2CCC (55)
Hydroxychloroquine
Melanoma
N.N. Petrov National Medical Research Center of OncologyP2CCC (55)
Leuporelin
Melanoma
Novartis PharmaceuticalsP2CCC (55)
Naltrexone
Melanoma
Sarah WeissP2CCC (55)
Recombinant Flt3 Ligand
Melanoma
University of Southern CaliforniaP2CCC (55)
Regorafenib
Melanoma
Neonc Technologies, Inc.P2CCC (55)
Veliparib
Melanoma
National Cancer Institute (NCI)P2CCC (55)
Abp 206
Melanoma
AmgenP3CCC (54)
Entrectinib
Melanoma
Cancer Research UKP2/3CCC (54)
Immunoglobulin, Anti-(Human Cd3 Antigen ?-Chain) (Human-Mus Musculus Single-Chain Fv Fragment Vl-((Ggggs)4Gggs)-Vh) Fusion Protein With Peptide Linker (Ggggs) Fusion Protein With T-Cell Receptor ? Chain [171-Cysteine,189-Alanine,203-Asparatic Acid] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment), Disulfide With T Cell Receptor ? Chain [163-Cysteine] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment)
Melanoma
Immunocore LtdP3CCC (54)
Infliximab
Melanoma
Massachusetts General HospitalP2CCC (54)
Mirdametinib
Melanoma
Kevin Kim, MDP2CCC (54)
Sonazoid
Melanoma
The Netherlands Cancer InstituteP2/3CCC (54)
Showing 51 to 100 of 435 assets
PreviousPage 2 of 9Next